Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma
- 30 September 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 49 (2), 223-227
- https://doi.org/10.1038/bmt.2013.150
Abstract
The achievement of CR is the crucial step for a prolonged PFS and OS after an autologous SCT in multiple myeloma (MM). Unfortunately, even with the use of new regimens and the current high CR rates, most, if not all, patients will ultimately relapse or progress. We analyzed the type of relapse or progression (asymptomatic vs symptomatic), clinical features including the presence of extramedullary involvement and time to next treatment in 211 patients who underwent melphalan-based autologous SCT over an 18-year period at our institution. After autologous SCT, serological or asymptomatic relapse/progression was observed in about one half of the patients. The treatment-free interval was significantly longer in patients relapsing from CR than in those progressing from PR (P=0.017). Patients with serological relapse/progression had a significantly longer OS than those relapsing from symptomatic disease (P=0.002). The relapse pattern was similar to the initial clinical presentation. Survival after relapse/progression was shorter in those patients with a 24-h urine M-protein excretion of at least 200 mg (P=0.048). Extramedullary involvement was frequent (24%), being the highest risk in patients with extramedullary involvement at diagnosis (P=0.001).Keywords
This publication has 23 references indexed in Scilit:
- Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM studyBlood, 2012
- Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients’ monitoring after transplantationBone Marrow Transplantation, 2012
- Redefining myelomaNature Reviews Clinical Oncology, 2012
- Long-term prognostic significance of response in multiple myeloma after stem cell transplantationBlood, 2011
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1Blood, 2011
- Hematopoietic stem cell transplantation for multiple myeloma beyond 2010Blood, 2010
- Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains.Haematologica, 2007
- Clinical outcomes with intensive therapy for patients with primary resistant multiple myelomaBone Marrow Transplantation, 2004
- High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remissionBone Marrow Transplantation, 2004
- Impact of complete remission with intensive therapy in patients with responsive multiple myelomaBone Marrow Transplantation, 2001